Type 2 Diabetes Clinical Trials in San Francisco, CA

About Type 2 Diabetes Clinical Trials in San Francisco

Type 2 diabetes is a chronic metabolic condition affecting over 37 million Americans, characterized by insulin resistance and progressive loss of beta-cell function. While metformin remains the first-line treatment, the treatment landscape has expanded dramatically with GLP-1 receptor agonists (semaglutide, tirzepatide), SGLT2 inhibitors (empagliflozin, dapagliflozin), and dual GIP/GLP-1 agonists showing both glycemic and cardiovascular benefits. Clinical trials are now exploring triple-hormone agonists, oral GLP-1 formulations, islet cell regeneration therapies, and precision medicine approaches that tailor treatment to individual metabolic profiles. Patients with uncontrolled HbA1c on current medications, those with diabetic complications, or newly diagnosed patients may qualify for enrollment.

There are currently 14 type 2 diabetes clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 82,306 participants. Research is being sponsored by University of South Florida, University of Michigan, Piomic Medical and 10 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.